Silence Therapeutics Reports Steep Revenue Decline, Doubled Net Loss, and AstraZeneca Drops SLN312 Program

summarizeSummary

Silence Therapeutics' financial health has deteriorated significantly, with collaboration revenue plummeting and net losses nearly doubling year-over-year. This indicates a substantial cash burn and raises concerns about future funding and operational runway. The decision by AstraZeneca to cease development of SLN312 is a major setback for Silence's pipeline, as it loses a key partner for a clinical asset. While the accelerated timeline for Divesiran's Phase 2 results is a positive, it is heavily overshadowed by the severe financial performance and the loss of a significant partnership. Investors should monitor the company's cash runway and its strategy for SLN312 and other pipeline assets.

check_boxKey Events

• Steep Revenue Decline

  Collaboration revenue fell dramatically from $43.3 million in 2024 to $0.6 million for the full year ended December 31, 2025.

• Net Loss Doubled

  The company's net loss increased to $88.6 million for 2025, nearly doubling from $45.3 million in 2024.

• AstraZeneca Terminates SLN312 Development

  AstraZeneca notified Silence Therapeutics that it will not pursue further development of SLN312 beyond Phase 1, returning exclusive global rights to Silence.

• Cash Position Decreased

  Cash, cash equivalents, and short-term investments declined to $85.1 million as of December 31, 2025, from approximately $147.3 million in 2024.

auto_awesomeAnalysis

Silence Therapeutics' financial health has deteriorated significantly, with collaboration revenue plummeting and net losses nearly doubling year-over-year. This indicates a substantial cash burn and raises concerns about future funding and operational runway. The decision by AstraZeneca to cease development of SLN312 is a major setback for Silence's pipeline, as it loses a key partner for a clinical asset. While the accelerated timeline for Divesiran's Phase 2 results is a positive, it is heavily overshadowed by the severe financial performance and the loss of a significant partnership. Investors should monitor the company's cash runway and its strategy for SLN312 and other pipeline assets.